PLASENTA AKREATA; GEÇMİŞTEN BUGÜNE ÖYKÜSÜ

Year 2020, Volume: 15 Issue: 3, 88 - 93, 16.10.2020

Sezen Koçarslan

https://doi.org/10.17517/ksutfd.738885

Cited By: 1

Abstract

Plasenta akreata plasental villusların miyometriyumu anormal invazyonu ile oluşur. Histopatoloji temelinde üç dereceye ayrılır. Plasental villuslar miyometriyum ile direkt temas kurduğunda plasenta akreata, miyometriyal katları invaze ettiğinde plasenta inkreata, uterin serozayı da invaze ettiğinde plasenta perkreata denir. Plasenta akreata için ana risk faktörü plasenta previa’nın eşlik ettiği sezeryan doğum öyküsüdür. Plasenta akreatada plasental yataktaki yetersiz desidualizasyon ve trofoblastik değişiklikler uterin skara sekonderdir. Maternal klinik gidişi yönetimde anahtar faktör antenatal tanıdır. Tanı vakaların çoğunda ultrason ile konulur. Plasenta akreatanın tedavisi multidisipliner cerrahi ekibe ihtiyaç duyar. Sezeryan histerektomi tercih edilen tedavidir. Seçilmiş vakalarda konservatif tedavi ile fertilite korunabilir.

Keywords

Plasenta, yapışma anomalisi, akreata, inkreata, perkreata

Supporting Institution

YOK

Thanks

Sayın Editör yayını değerlendirmek için değerli zamanınızı ayırdığınız için şimdiden teşekkür ederim. Saygılarımla

References

• 1. Irving C, Hertig AT. A study of placenta accreta. Surg Gynecol Obstet 1937;64:178-200.
• 2. Luke RK, Sharpe JW, Greene RR. Placenta accreta: the adherent or invasive placenta. Am J Obstet Gynecol 1966;95:660-8.
• 3. Fox H. Placenta accreta: 1945-1969. Obstet Gynecol Surv 1972;27:475-90.
• 4. Benirschke K, Burton GJ, Baergen RN. Pathology of the human placenta, 6th ed. Berlin: Springer-Verlag; 2012.
• 5. Jauniaux E, Moffett A, Burton GJ. Placental Implantation Disorders. Obstet Gynecol Clin North Am. 2020 Mar;47(1):117-132.
• 6. Solheim KN, Esakoff TF, Little SE, Cheng YW, Sparks TN, Caughey AB. The effect of cesarean delivery rates on the future incidence of placenta previa, placenta accreta, and maternal mortality. J Matern Fetal Neonatal Med 2011;24:1341-6.
• 7. Balayla J, Bondarenko HD. Placenta accreta and the risk of adverse maternal and neonatal outcomes. J Perinat Med 2013;41:141-9.
• 8. Silver BM. Abnormal placentation: placenta previa, vasa previa and placenta accreta. Obstet Gynecol 2015;126:654-68.
• 9. Wong HS, Cheung YK, Zuccollo J, Tait J, Pringle KC. Evaluation of sonographic diagnostic criteria for placenta accreta. J Clin Ultrasound. 2008 Nov-Dec;36(9):551-9
• 10. Hung TH, Shau WY, Hsieh CC, Chiu TH, Hsu JJ, Hsieh TT. Risk factors for placenta accreta. Obstet Gynecol. 1999 Apr;93(4):545-50.
• 11. Bauer ST, Bonanno C. Abnormal placentation. Semin Perinatol. 2009 Apr;33(2):88-96.
• 12. Wu S, Kocherginsky M, Hibbard JU. Abnormal placentation: twenty-year analysis. Am J Obstet Gynecol. 2005 May;192(5):1458-61.
• 13. Hull AD, Moore TR. Multiple repeat cesareans and the threat of placenta accreta: incidence, diagnosis, management. Clin Perinatol. 2011 Jun;38(2):285-96.
• 14. Fox H, Sebire N.Pathology of the placenta. 3th ed. Philedelphia: Saunders&Elsevier; 2007.
• 15. Freeman RM. Placenta accreta and myotonic dystrophy. Two case reports. Br J Obstet Gynaecol. 1991 Jun;98(6):594-5.
• 16. Maouris P. Pregnancy after planned partial endometrial resection. Aust N Z J Obstet Gynaecol. 1994 Feb;34(1):122-3.
• 17. Smith RP. Placenta accreta is associated with IVF pregnancies: a retrospective chart review. BJOG. 2012 Jan;119(1):111-2
• 18. Beuker JM, Erwich JJ, Khong TY. Is endomyometrial injury during termination of pregnancy or curettage following miscarriage the precursor to placenta accreta? J Clin Pathol 2005;58:273-5.
• 19. Bernischke K, Kaufmann P. Pathology of the human placenta. 3rd ed. New York: Springer Science & Business Media; 2013.
• 20. Kaufmann P, Burton GJ. Anatomy and Genesis of the placenta. In: Knobil E, Neill JD, editors. The Physiology of Reproduction. 2nd ed. New York: Raven Press; 1994.
• 21. Pijnenborg R, Dixon G, Robertson WB, Brosens I. Trophoblastic invasion of human decidua from 8 to 18 weeks of pregnancy. Placenta. 1980 Jan;1(1):3-19
• 22. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta. 2009 Jun;30(6):473-82.
• 23. Miller WG. A clinical and pathological study of placenta accreta. J Obstet Gynaecol Br Emp. 1959 Jun;66:353-64
• 24. Khong TY, Robertson WB. Placenta creta and placenta praevia creta. Placenta 1987;8:399-409.
• 25. Tantbirojn P, Crum CD, Parast MM. Pathophysiology of placenta creta: the role of deciduas and extravillous cytotrophoblast. Placenta 2008;29:639-45.
• 26. Strickland S, Richards WG. Invasion of the trophoblasts. Cell 1992;71: 355-7.
• 27. Wehrum MJ, Buhimschi IA, Salafia C, Thung S, Bahtiyar MO, Werner EF et al. Accreta complicating complete placenta previa is characterized by reduced systemic levels of vascular endothelial growth factor and by epithelial-to-mesenchymal transition of the invasive trophoblast. Am J Obstet Gynecol. 2011 May;204(5):411.e1-411.e11.
• 28. Khong TY. The pathology of placenta accreta, a worldwide epidemic. J Clin Pathol 2008;61:1243-6.
• 29. Kim KR, Jun SY, Kim JY, Ro JY. Implantation site intermediate trophoblast in placenta cretas. Mod Pathol 2004;17:1483-90.
• 30. Cohen M, Wuillemin C, Irion O, Bischof P. Role of decidua in trophoblastic invasion. Neuroendocrinology Letters. 2010; 31(2):193-7.
• 31. Stanek J, Drummond Z. Occult placenta accreta: the missing link in the diagnosis of abnormal placentation. Pediatr Dev Pathol 2007;10:266-73.
• 32. Hilali N, Kocarslan S, Vural M, Incebiyik A, Camuzcuoglu A, Camuzcuoglu H. Ki-67 proliferation index in patients with placenta previa percreta in the third trimester. Wien Klin Wochenschr. 2015 Feb;127(3-4):98-102.
• 33. Tseng JJ, Hsu SL, Wen MC, Ho ES, Chou MM. Expression of epidermal growth factor receptor and c-erbb-2 oncoprotein in trophoblast populations of placenta accrete. Am J Obstet Gynecol 2004 Dec;191(6):2106-13.
• 34.Tseng JJ, Chou MM, Hsieh YT, Wen MC, Ho ES, Hsu SL. Differential expression of vascular endothelial growth factor, placenta growth factor and their receptors in placentae from pregnancies complicated by placenta accreta. Placenta. 2006 Jan;27(1):70-8.
• 35. Tseng JJ, Hsu SL, Ho ES, Hsieh YT, Wen MC, Chou MM. Differential expression of angiopoietin-1, angiopoietin-2, and Tie receptors in placentas from pregnancies complicated by placenta accreta. Am J Obstet Gynecol. 2006 Feb;194(2):564-71.
• 36. McCool RA, Bombard AT, Bartholomew DA, Calhoun BC. Unexplained positive/elevated maternal serum alpha-fetoprotein associated with placenta increta. A case report. J Reprod Med. 1992 Sep;37(9):826-8.
• 37. Incebiyik A, Kocarslan S, Camuzcuoglu A, Hilali NG, Incebiyik H, Camuzcuoglu H. Trophoblastic E-cadherin and TGF-beta expression in placenta percreta and normal pregnancies. J Matern Fetal Neonatal Med. 2016;29(1):126-9.
• 38. Özer A, Yaylalı A, Koçarslan S. The role of osteopontin in the pathogenesis of placenta percreta. Ginekol Pol. 2018;89(8):437-41.
• 39. Knöfler M. Critical growth factors and signalling pathways controlling human trophoblast invasion. Int J Dev Biol 2010;54:269-80.
• 40. Ahmed A, Dunk C, Ahmad S, Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen--a review. Placenta. 2000 Mar;21 Suppl A:16-24.
• 41. Lockwood CJ, Krikun G, Hausknecht VA, Papp C, Schatz F. Matrix metalloproteinase and matrix metalloproteinase inhibitor expression in endometrial stromal cells during progestin-initiated decidualization and menstruation-related progestin withdrawal. Endocrinology. 1998 Nov;139(11):4607-13.
• 42. Kocarslan S, Incebıyık A, Guldur ME, Ekinci T, Ozardali HI. What is the role of matrix metalloproteinase-2 in placenta percreta? J Obstet Gynaecol Res. 2015 Jul;41(7):1018-22.
• 43. Ke Y, Lu JH, Yang BL, Guo HQ, Ma QY, Zhu H et al. Involvement of matrix metalloproteinase-2, -9, and tissue inhibitors of metalloproteinase-1, 2 in occurrence of the accrete placenta. Zhonghua Fu Chan Ke Za Zhi. 2006 May;41(5):311-4.
• 44. Tseng JJ, Chou MM. Differential expression of growth-, angiogenesis- and invasion related factors in the development of placenta accreta. Taiwan J Obstet Gynecol 2006;45:100 6.
• 45. Earl U, Bulmer JN, Briones A. Placenta accreta: an immunohistological study of trophoblast populations. Placenta. 1987 May-Jun;8(3):273-82.
• 46. Garmi G, Goldman S, Shalev E, Salim R. The effects of decidual injury on the invasion potential of trophoblastic cells. Obstet Gynecol. 2011 Jan;117(1):55-9.
• 47. Shih JC, Palacios Jaraquemada JM, Su YN, Shyu MK, Lin CH, Lin SY et al. Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol. 2009 Feb;33(2):193-203.
• 48. Levine D, Hulka CA, Ludmir J, Li W, Edelman RR. Placenta accreta: evaluation with color Doppler US, power Doppler US, and MR imaging. Radiology. 1997 Dec;205(3):773-6.
• 49. Jauniaux E, Collins S, Burton GJ. Placenta accreta spectrum: pathophysiology and evidence-based anatomy for prenatal ultrasound imaging. Am J Obstet Gynecol. 2018 Jan;218(1):75-87.